A new treatment against Clostridium difficile

被引：0

作者：

Erb, William ^{[1
]}

Zhu, Jieping ^{[2
]}

机构：

[1] Univ Bristol, Sch Chem, Bristol BS8 1TH, Avon, England

[2] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, EPFL SB ISIC LSPN, CH-1015 Lausanne, Switzerland

来源：

ACTUALITE CHIMIQUE | 2012年 / 360期

关键词：

Clostridium difficile; infections; diarrheas; COD; fidaxomicin; tiacumicin; antibiotics therapy; ARMENIACA SUBSP NOV; IN-VITRO ACTIVITIES; BACTERIAL TRANSCRIPTION; NATURAL-PRODUCTS; RNA-POLYMERASE; LIPIARMYCIN; ANTIBIOTICS; INFECTION; VANCOMYCIN; DIARRHEA;

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

A new treatment against Clostridium difficile Clostridium difficile associated diarrheas (ODD) are one of the major secondary infections encountered in patients under antibiotics therapy. In spite of inherent drawbacks associated with vancomycin and metronidazole, these two broad-spectrum antibiotics are currently prescribed for the treatment of ODD. The natural molecule known as tiacumicin B or fidaxomicin has recently been approved by FDA to treat Clostridium difficile infections. This article briefly recalls the essential of antibiotics, of Clostridium difficile and discusses the isolation, biosynthesis, mode of action and structure-activity relationship of tiacumicin B.

引用

页码：83 / 89

页数：7

共 50 条

[21] Fidaxomicin - the new drug for Clostridium difficile infection
Vaishnavi, Chetana
INDIAN JOURNAL OF MEDICAL RESEARCH, 2015, 141 : 398 - 407
[22] Oncologic aspects of Clostridium difficile
Andras, Telekes
ORVOSI HETILAP, 2016, 157 (28) : 1110 - 1116
[23] A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile
Endres, Bradley T.
Basseres, Eugenie
Memariani, Ali
Chang, Long
Alam, M. Jahangir
Vickers, Richard J.
Kakadiaris, Ioannis A.
Garey, Kevin W.
ANAEROBE, 2016, 40 : 10 - 14
[24] Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
Venugopal, Anilrudh A.
Johnson, Stuart
CLINICAL INFECTIOUS DISEASES, 2012, 54 (04) : 568 - 574
[25] Kibdelomycin Is a Potent and Selective Agent against Toxigenic Clostridium difficile
Miesel, Lynn
Hecht, David W.
Osmolski, James R.
Gerding, Dale
Flattery, Amy
Li, Fangbiao
Lan, Jing
Lipari, Philip
Polishook, Jon D.
Liang, Lianzhu
Liu, Jenny
Olsen, David B.
Singh, Sheo B.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) : 2387 - 2392
[26] Curcumin: A natural derivative with antibacterial activity against Clostridium difficile
Mody, Deepansh
Athamneh, Ahmad I. M.
Seleem, Mohamed N.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 21 : 154 - 161
[27] Effect of Age on Treatment Outcomes in Clostridium difficile Infection
Louie, Thomas J.
Miller, Mark A.
Crook, Derrick W.
Lentnek, Arnold
Bernard, Louis
High, Kevin P.
Shue, Youe-Kong
Gorbach, Sherwood L.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 (02) : 222 - 230
[28] Faecal transplantation for the treatment of Clostridium difficile infection: a review
McCune, V. L.
Struthers, J. K.
Hawkey, P. M.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (03) : 201 - 206
[29] Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection
Abreu y Abreu, A. T.
Velarde-Ruiz Velasco, J. A.
Zavala-Solares, M. R.
Remes-Troche, J. M.
Carmona-Sanchez, R. I.
Aldana-Ledesma, J. M.
Camacho-Ortiz, A.
Contreras-Omana, R.
Diaz-Seoane, R.
Elizondo-Vazquez, C. T.
Garza-Gonzalez, E.
Grajales-Figueroa, G.
Gomez-Escudero, O.
Jacobo-Karam, J. S.
Morales-Arambula, M.
Olivares-Guzman, L. O.
Sifuentes-Osornio, J.
Siu-Moguel, A. G.
Soto-Solis, R.
Valdovinos-Garcia, L. R.
Valdovinos-Diaz, M. A.
Vazquez-Elizondo, G.
la Vega Jasso, S. A. Lazo-de
REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2019, 84 (02): : 204 - 219
[30] Effect of Treatment Variation on Outcomes in Patients with Clostridium difficile
Brown, Adam T.
Seifert, Charles F.
AMERICAN JOURNAL OF MEDICINE, 2014, 127 (09) : 865 - 870

← 1 2 3 4 5 →